Eyeliss is a cosmetic-research peptide blend associated with studies on microcirculation, extracellular-matrix interactions, and fluid homeostasis in skin models. Component peptides feature charged and lipophilic residues that modulate diffusion and binding to matrix proteins. Researchers evaluate its effects on capillary-mimetic systems and dermal cell cultures. Applications span cosmetic peptide screening, formulation optimization, and skin-biology research.
CAT No: R2722
CAS No:24292-52-2
Synonyms/Alias:Hesperidin methylchalcone;24292-52-2;Hesperidin methyl chalcone;EYELISS;hesperidine methylchalcone;EINECS 246-128-2;UNII-4T2GVA922X;4T2GVA922X;(E)-1-(4-((6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-2-hydroxy-6-methoxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)-2-propen-1-one;DTXSID90885262;(E)-3-(3-hydroxy-4-methoxyphenyl)-1-[2-hydroxy-6-methoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxyphenyl]prop-2-en-1-one;HESPERIDIN METHYL CHALCONE [VANDF];HESPERIDIN METHYL CHALCONE [WHO-DD];2-Propen-1-one, 1-(4-((6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-2-hydroxy-6-methoxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)-, (2E)-;2-Propen-1-one, 1-[4-[[6-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-2-hydroxy-6-methoxyphenyl]-3-(3-hydroxy-4-methoxyphenyl)-, (2E)-;Chalcone, 2',3,4'-trihydroxy-4,6'-dimethoxy-, 4'-(6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranoside);MFCD00010438;(E)-1-(4-((6-O-(6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)-.BETA.-D-GLUCOPYRANOSYL)OXY)-2-HYDROXY-6-METHOXYPHENYL)-3-(3-HYDROXY-4-METHOXYPHENYL)-2-PROPEN-1-ONE;(E)-3-(3-Hydroxy-4-methoxyphenyl)-1-(2-hydroxy-6-methoxy-4-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)phenyl)prop-2-en-1-one;2-PROPEN-1-ONE,1-(4-((6-O-(6-DEOXY-ALFA-L-MANNOPYRANOSYL)-.BETA.-D-GLUCOPYRANOSYL)OXY)-2-HYDROXY-6-METHOXYPHENYL)-3-(3-HYDROXY-4-METHOXYPHENYL)-, (E)-;hesperidin methyl chalone;(E)-1-[4-[[6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-2-hydroxy-6-methoxyphenyl]-3-(3-hydroxy-4-methoxyphenyl)-2-propen-1-one;(E)-3-(3-hydroxy-4-methoxyphenyl)-1-(2-hydroxy-6-methoxy-4-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl)oxymethyl)oxan-2-yl)oxyphenyl)prop-2-en-1-one;SCHEMBL3452314;CHEMBL5435071;FDHNLHLOJLLXDH-JIYHLSBYSA-N;DTXCID401024653;STK801860;AKOS015895097;OH34622;HESPERIDIN METHYL CHALCONE [INCI]
1. TMEM16F and dynamins control expansive plasma membrane reservoirs
5. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More